Access
eHealth Week Looks at Challenges, Solutions and Success Stories
The 2013 eHealth week concluded yesterday, after 3 days of events that brought together industry partners, healthcare professionals, and decision-makers from across Europe to discuss the current possibilities and challenges facing eHealth. The event also offered the opportunity to celebrate eHealth success stories and raise awareness around the eHealth movement.
Annual Conference on European Pharmaceutical Law, 11 - 12 April 2013, Brussels (Belgium)
This annual conference will provide practitioners with an analysis of the constantly growing measures to promote patient access to information on medicinal products that have been introduced since the review of EU pharmaceutical legislation which entered into force in 2005.
Cuts, Cuts, Cuts!-But what about innovation?
EFPIAs Director General Richard Bergström puts forward his views on the hot topic of the EU budget and the importance of preserving innovation.
Call for a Free Trade Agreement with Japan Joint statement by European business organisation
The signatories of this statement strongly call upon the EU and Japan to launch the negotiations for a deep and comprehensive Free Trade Agreement (FTA) as soon as possible. An FTA will deliver significant economic benefits and contribute to the development of both the EU and Japan.
Interpol crackdown on illicit online pharmacies
11.10.2012, Brussels: Interpol last week announced the seizure of over 3.75million units of counterfeit medicines worth over 10million USD. Operation Pangea V - the largest internet based action targeting black market and fake of illicit medicines- spanned over 100 countries and resulted in over 80 arrests. The operation ran from September 25 to October 2.
Patients' W.A.I.T. Indicator - Report 2010
The latest edition shows that, depending on the patients' country of residence, doctors would be able to prescribe between 39% and 86% of the new medicines with a valid EU marketing authorisation granted between 1 January 2007 and 31 December 2009. For those new medicines that doctors can prescribe under the national healthcare provisions, average time elapsing between the date of EU market authorisation and the "accessibility" date in 14 European countries will vary from 88 to 392 days.
Tackling the rise of counterfeit medicines
A recent report published by the European Commission showed the growing threat of counterfeit medicines ordered over the internet – and industry bodies must work together to tackle the problem
Market Access Delays
President of EFPIA calls for pharma innovation to be a key part of a European growth strategy
Europe must make choices to remain a home for biomedical innovation.
